secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001437749-25-027191
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex gets US and EU patent allowances for REQORSA combo with PD-L1/PD-1 antibodies; trial underway
--------------------------------------------------------------------------------

- USPTO issued notice of allowance for patent covering REQORSA + PD-L1 antibodies (e.g., Tecentriq); EPO issued allowance for REQORSA + PD-1 antibodies; both expire 2037.
- Korea granted patent for REQORSA + PD-L1 antibodies; Genprex pursuing additional patents in Europe, Canada, Brazil, China, Israel for Acclaim-3 trial.
- Patents for REQORSA + PD-1 antibodies already granted in US, Japan, Mexico, Russia, Australia, Chile, China, Korea, and Singapore.
- Acclaim-3 Phase 1/2 trial testing REQORSA + Tecentriq maintenance in ES-SCLC has FDA Fast Track and Orphan Drug Designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925027191/0001437749-25-027191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925027191/gnpx20250815_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-027191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer